Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript November 7, 2024
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.18.
Operator: Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded. I would now like to hand the conference over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. Please go...
